The	O	0,3
manifestations	O	4,18
of	O	19,21
Lyme	B-KP	22,26
disease	I-KP	27,34
are	O	35,38
routinely	O	39,48
treated	O	49,56
with	O	57,61
antibiotics;	B-KP	62,74
therapy	O	75,82
hastens	O	83,90
the	O	91,94
resolution	O	95,105
and	O	106,109
largely	O	110,117
prevents	O	118,126
the	O	127,130
development	O	131,142
of	O	143,145
other	O	146,151
disease	O	152,159
manifestations.	O	160,175

The	O	176,179
classes	O	180,187
of	O	188,190
antibiotics	B-KP	191,202
that	O	203,207
have	O	208,212
shown	O	213,218
the	O	219,222
greatest	O	223,231
effectiveness	O	232,245
against	O	246,253
Borrelia	B-KP	254,262
spirochetes	I-KP	263,274
is	O	275,277
b-lactams	B-KP	278,287
(in	O	288,291
particular	O	292,302
cephalosporins)	O	303,318
tetracyclines	B-KP	319,332
and,	O	333,337
to	O	338,340
a	O	341,342
lesser	O	343,349
extent,	O	350,357
macrolides.	B-KP	358,369

The	O	370,373
best	O	374,378
treatment	O	379,388
approach,	O	389,398
in	O	399,401
particular	O	402,412
the	O	413,416
duration	O	417,425
of	O	426,428
therapy,	O	429,437
is	O	438,440
a	O	441,442
matter	O	443,449
of	O	450,452
ongoing	O	453,460
debate.	O	461,468

It	O	469,471
is	O	472,474
quite	O	475,480
evident	O	481,488
that	O	489,493
not	O	494,497
all	O	498,501
patients,	O	502,511
and	O	512,515
most	O	516,520
certainly	O	521,530
not	O	531,534
all	O	535,538
species	O	539,546
or	O	547,549
strains	O	550,557
of	O	558,560
Borrelia	B-KP	561,569
[113]	O	570,575
respond	O	576,583
equally	O	584,591
to	O	592,594
the	O	595,598
antibiotics	B-KP	599,610
most	O	611,615
commonly	O	616,624
used	O	625,629
in	O	630,632
the	O	633,636
treatment	O	637,646
of	O	647,649
Lyme	B-KP	650,654
disease.	I-KP	655,663

Based	O	664,669
on	O	670,672
the	O	673,676
available	O	677,686
evidence	O	687,695
from	O	696,700
randomized	B-KP	701,711
controlled	I-KP	712,722
trials	I-KP	723,729
(RCTs),	B-KP	731,738
treatment	O	739,748
recommendations	O	749,764
have	O	765,769
been	O	770,774
published	O	775,784
by	O	785,787
the	O	788,791
Infectious	O	792,802
Diseases	O	803,811
Society	O	812,819
of	O	820,822
America	O	823,830
(IDSA)	O	831,837
[221],	O	838,844
the	O	845,848
American	O	849,857
Academy	O	858,865
of	O	866,868
Pediatrics	O	869,879
[271],	O	880,886
and	O	887,890
by	O	891,893
a	O	894,895
variety	O	896,903
of	O	904,906
national	O	907,915
and	O	916,919
supranational	O	920,933
associations	O	934,946
in	O	947,949
Europe	O	950,956
[203,272]	O	957,966
(www.eucalb.com).	O	967,984

As	O	985,987
the	O	988,991
comparison	O	992,1002
between	O	1003,1010
the	O	1011,1014
guidelines	O	1015,1025
published	O	1026,1035
by	O	1036,1038
the	O	1039,1042
IDSA	O	1043,1047
and	O	1048,1051
the	O	1052,1055
EUCALB	O	1056,1062
in	O	1063,1065
Table	O	1066,1071
4	O	1072,1073
illustrates,	O	1074,1086
the	O	1087,1090
approaches	O	1091,1101
to	O	1102,1104
therapy	O	1105,1112
are	O	1113,1116
largely	O	1117,1124
similar	O	1125,1132
on	O	1133,1135
both	O	1136,1140
sides	O	1141,1146
of	O	1147,1149
the	O	1150,1153
Atlantic,	O	1154,1163
but	O	1164,1167
there	O	1168,1173
are	O	1174,1177
some	O	1178,1182
minor	O	1183,1188
differences	O	1189,1200
in	O	1201,1203
the	O	1204,1207
recommended	O	1208,1219
dosage	O	1220,1226
and	O	1227,1230
treatment	O	1231,1240
duration.	O	1241,1250

Note	O	1251,1255
that	O	1256,1260
the	O	1261,1264
International	O	1265,1278
Lyme	O	1279,1283
and	O	1284,1287
Associated	O	1288,1298
Diseases	O	1299,1307
Society	O	1308,1315
has	O	1316,1319
also	O	1320,1324
published	O	1325,1334
guidelines	O	1335,1345
for	O	1346,1349
the	O	1350,1353
management	O	1354,1364
of	O	1365,1367
Lyme	I-KP	1368,1372
disease	I-KP	1373,1380
[273].	O	1381,1387

These	O	1388,1393
advocate	O	1394,1402
more	O	1403,1407
aggressive	O	1408,1418
and	O	1419,1422
longer	O	1423,1429
treatment	O	1430,1439
courses	O	1440,1447
for	O	1448,1451
patients	O	1452,1460
with	O	1461,1465
persistent	O	1466,1476
symptoms	O	1477,1485
or	O	1486,1488
refractory	O	1489,1499
disease,	O	1500,1508
but	O	1509,1512
much	O	1513,1517
of	O	1518,1520
the	O	1521,1524
terminology	O	1525,1536
is	O	1537,1539
poorly	O	1540,1546
defined	O	1547,1554
and	O	1555,1558
the	O	1559,1562
cited	O	1563,1568
“evidence”	O	1569,1579
is	O	1580,1582
largely	O	1583,1590
restricted	O	1591,1601
to	O	1602,1604
older	O	1605,1610
studies	O	1611,1618
that	O	1619,1623
support	O	1624,1631
such	O	1632,1636
an	O	1637,1639
approach	O	1640,1648
and	O	1649,1652
ignores	O	1653,1660
much	O	1661,1665
of	O	1666,1668
the	O	1669,1672
other	O	1673,1678
available	O	1679,1688
evidence.	O	1689,1698

The	O	1699,1702
results	O	1703,1710
of	O	1711,1713
several	O	1714,1721
RCTs	I-KP	1722,1726
and	O	1727,1730
a	O	1731,1732
large	O	1733,1738
retrospective	O	1739,1752
study	O	1753,1758
do	O	1759,1761
not	O	1762,1765
show	O	1766,1770
any	O	1771,1774
benefit	O	1775,1782
in	O	1783,1785
extending	O	1786,1795
the	O	1796,1799
duration	O	1800,1808
of	O	1809,1811
treatment	O	1812,1821
with	O	1822,1826
doxycycline	I-KP	1827,1838
from	O	1839,1843
10	O	1844,1846
days	O	1847,1851
to	O	1852,1854
15	O	1855,1857
or	O	1858,1860
20	O	1861,1863
days	O	1864,1868
in	O	1869,1871
patients	O	1872,1880
with	O	1881,1885
EM	I-KP	1886,1888
[274-276].	O	1889,1899

Retrospectively	O	1900,1915
obtained	O	1916,1924
data	O	1925,1929
suggest	O	1930,1937
a	O	1938,1939
similar	O	1940,1947
conclusion	O	1948,1958
for	O	1959,1962
amoxicillin	I-KP	1963,1974
[276].	O	1975,1981

In	O	1982,1984
another	O	1985,1992
double-blind	O	1993,2005
RCT,	O	2006,2010
treatment	O	2011,2020
of	O	2021,2023
patients	O	2024,2032
with	O	2033,2037
disseminated	O	2038,2050
Lyme	I-KP	2051,2055
borreliosis	I-KP	2056,2067
with	O	2068,2072
a	O	2073,2074
3-week	O	2075,2081
course	O	2082,2088
of	O	2089,2091
i.v.	O	2092,2096

ceftriaxone	O	2097,2108
followed	O	2109,2117
by	O	2118,2120
100	O	2121,2124
days	O	2125,2129
of	O	2130,2132
amoxicillin	I-KP	2133,2144
did	O	2145,2148
not	O	2149,2152
improve	O	2153,2160
the	O	2161,2164
outcome	O	2165,2172
compared	O	2173,2181
to	O	2182,2184
a	O	2185,2186
3-week	O	2187,2193
course	O	2194,2200
of	O	2201,2203
ceftriaxone	I-KP	2204,2215
alone	O	2216,2221
[277].	O	2222,2228

These	O	2229,2234
findings	O	2235,2243
do	O	2244,2246
not	O	2247,2250
exclude	O	2251,2258
that	O	2259,2263
some	O	2264,2268
patients	O	2269,2277
may	O	2278,2281
benefit	O	2282,2289
from	O	2290,2294
longer	O	2295,2301
or	O	2302,2304
more	O	2305,2309
aggressive	O	2310,2320
therapy,	O	2321,2329
but	O	2330,2333
the	O	2334,2337
risk-benefit	O	2338,2350
ratio	O	2351,2356
has	O	2357,2360
to	O	2361,2363
be	O	2364,2366
carefully	O	2367,2376
weighed	O	2377,2384
for	O	2385,2388
each	O	2389,2393
individual	O	2394,2404
patient.	O	2405,2413

